MOTS-c + BPC-157 is a two-peptide research blend that pairs a mitochondrial-genome-encoded metabolic-regulator peptide with a synthetic gastric pentadecapeptide studied preclinically for cytoprotection and tissue repair. Of the blends in this library it is one of the least mechanistically intuitive: the two components come from largely separate literatures — metabolism and exercise biology on one side, injury repair on the other. The combination itself has never been studied.
The blend contains two distinct peptides. MOTS-c ("mitochondrial open reading frame of the twelve-S rRNA type-c") is a 16-amino-acid peptide encoded within the mitochondrial genome, in a short open reading frame inside the 12S rRNA region [1]. BPC-157 is a synthetic 15-amino-acid peptide corresponding to a fragment of a protein identified in human gastric juice [2]. There is no single molecular formula for the blend; each component retains its own identity and the proportion of each is set by the vendor. VialTalk does not currently track a catalog listing for this blend, so no catalog vial label is given here.
MOTS-c — metabolic signalling. MOTS-c is described as a metabolic regulator whose most-reported mechanism is activation of AMPK, with downstream effects on glucose handling and insulin sensitivity; it has also been reported to translocate to the nucleus under metabolic stress [1]. In cultured cells, MOTS-c raised markers of mitochondrial biogenesis and the mitochondrial fusion proteins OPA1 and MFN2, and fusion was required for MOTS-c-induced GLUT4 translocation [3]. A study combining human participants and laboratory models reported that MOTS-c facilitated trafficking of the membrane-repair protein TRIM72 to the muscle cell membrane and attenuated membrane damage in vitro [4]. Not all findings point one way: in adipose-derived mesenchymal stromal cells from donors with obesity, exogenous MOTS-c activated AMPK signalling but blunted the cells' reparative function [5].
BPC-157 — repair signalling. Reported mechanisms, which remain hypothesised, include VEGFR2-linked angiogenesis and modulation of the nitric oxide system [2]. A 2025 review describes Akt-eNOS and ERK1/2 involvement and fibroblast activation, particularly in poorly vascularised tissue such as tendon [8]. In rat tendon fibroblasts, BPC-157 increased cell survival under oxidative stress and cell migration, with FAK and paxillin activation [9].
The rationale for pairing them. The pairing is usually framed as metabolic and mitochondrial support (MOTS-c) alongside local tissue-repair signalling (BPC-157), most often in recovery and athletic-performance discussions. Both appear together in a 2026 sports-medicine review of unapproved peptides, which notes favourable animal findings for many such peptides but scarce rigorous human safety data [12]. The rationale is a hypothesis; the mesenchymal stromal cell finding [5] is a reminder that a metabolic activator is not automatically pro-repair.
No study of MOTS-c and BPC-157 given together was found. A PubMed search combining the two names returned two records, both reviews that discuss each peptide separately among many others: a 2026 narrative review of approved and unapproved peptides in sports medicine [12] and a 2026 review of FDA compounding-committee evaluations of synthetic peptides [13]. Neither reports an experiment testing the two together.
Evidence tiers by component:
The published work covers each peptide only on its own [1][2][12]. Nothing is known about interaction between the two, co-formulation stability, or whether MOTS-c's metabolic effects alter BPC-157's reported activity or vice versa.
The "exercise-mimetic" description sometimes attached to MOTS-c is more marketing than established science [1], and the breadth of effects reported for BPC-157 in animal models warrants a sceptical read until human data exist [2]. Blending the two adds to that uncertainty rather than resolving it. Treat it as two separately characterised, largely preclinical compounds, not a validated formulation.
Store the sealed lyophilized product frozen or refrigerated, dry and protected from light, and avoid repeated freeze–thaw. Default to the more conservative storage window of the two components.
A meaningful COA must confirm identity of both peptides by mass spectrometry and report HPLC purity for each, with a per-component content breakdown rather than a single total. MOTS-c is a defined 16-mer and BPC-157 a defined 15-mer, so mass confirmation should match each expected molecular weight [1][2]. BPC-157 sequence-incorrect and under-filled product is a known market problem [2], and MOTS-c's popularity relative to its thin evidence base warrants sourcing scepticism [1].
[1] VialTalk monograph — MOTS-c — https://vialtalk.com/forum/peptide-research-library/mots-c-research-monograph-mitochondrial-peptide-metabolic
[2] VialTalk monograph — BPC-157 — https://vialtalk.com/forum/peptide-research-library/bpc-157-research-monograph-structure-mechanism-evidence
[3] Mitofusion is required for MOTS-c induced GLUT4 translocation — https://pubmed.ncbi.nlm.nih.gov/34253808/
[4] MOTS-c participates in plasma membrane repair via TRIM72 translocation — https://pubmed.ncbi.nlm.nih.gov/39267782/
[5] MOTS-c blunts reparative function in human mesenchymal stromal cells (2026) — https://pubmed.ncbi.nlm.nih.gov/42324588/
[6] Acute exercise and circulating mitochondrial-derived peptides in humans — https://pubmed.ncbi.nlm.nih.gov/34351816/
[7] NCT07505745 — MOTS-c for insulin sensitivity in prediabetes (Phase 2a, recruiting) — https://clinicaltrials.gov/study/NCT07505745
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025) — https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] BPC 157 tendon healing: outgrowth, cell survival and migration (rat tendon fibroblasts) — https://pubmed.ncbi.nlm.nih.gov/21030672/
[10] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
[11] NCT07437547 — BPC 157 for hamstring strain (Phase 2, recruiting) — https://clinicaltrials.gov/study/NCT07437547
[12] Mendias & Awan, Sports Med 2026 — Approved and Unapproved Peptide Therapies — https://pubmed.ncbi.nlm.nih.gov/41966639/
[13] Willis & Vu, Int J Pharm Compd 2026 — Synthetic Peptides in Pharmacy Compounding — https://pubmed.ncbi.nlm.nih.gov/42752426/
Research-use note: This monograph is an educational summary of the published literature on MOTS-c and BPC-157. The MOTS-c + BPC-157 combination has not been studied in any published human or animal experiment known to VialTalk, and neither peptide is an approved drug. Nothing here is medical advice or a usage recommendation.
